Comparison · NCT04620135-sae
Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle vs Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle vs Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%: serious adverse events. Trial comparisons, record NCT04620135-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04620135-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0305 | wilson | |
| Risk in group 2 | 0.0163 | 0.00447 | 0.0574 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0163 | -0.0574 | 0.0165 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
Number needed to treat, for one fewer participant with a serious adverse event on Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle than on Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% | 61.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | 1 drop netarsudil 0.02% in the evening and 1 drop netarsudil vehicle in the morning in each eye.~Netarsudil ophthalmic solution 0.02%: Topical sterile ophthalmic solution Other Name: Rhopressa® | 0 | 122 | EG000 |
| Group 2 | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% | 1 drop ripasudil twice daily in the morning and evening in each eye.~Ripasudil hydrochloride hydrate ophthalmic solution 0.4%: Other Name: Glanatec® | 2 | 123 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Volunteered or solicited AEs were collected from the time the subject received the first dose of study medication until Week 4 (Day 29) or study discontinuation. Unresolved AEs at the time of study exit were followed with proper medical care until the event was considered resolved or stabilized, the subject was lost to follow-up, or another resolution to the event was identified.
Source ClinicalTrials.gov
Trial
- Title
Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
- NCT number
- NCT04620135
- Phases
- PHASE3
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Netarsudil ophthalmic solution 0.02%, Ripasudil hydrochloride hydrate ophthalmic solution 0.4%
- Lead sponsor
- Aerie Pharmaceuticals
- Results first posted
- 2023-02-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04620135?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04620135-sae